GlassScriptPhysician profile
Nathan Sanborn
NPI 1235861022
$3,727.86
in general payments reported to CMS, 2019-2025
37 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $58.85 · 2023: $1,149 · 2024: $1,285 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.70 | 2023-2025 | |
| Lilly USA, LLC | $393.66 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $342.13 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $239.09 | 2024-2025 | Veozah |
| Novo Nordisk INC | $213.81 | 2023-2024 | Rybelsus, Ozempic |
| Aimmune Therapeutics, INC. | $186.48 | 2024-2025 | Zenpep, Vowst |
| Axsome Therapeutics, INC. | $154.85 | 2024-2025 | Auvelity, Sunosi, Symbravo |
| Amgen INC. | $122.31 | 2023-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $118.15 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $105.75 | 2024-2025 | Rexulti |
| Edwards Lifesciences Corporation | $89.74 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Neurocrine Biosciences, INC. | $80.46 | 2024-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $66.26 | 2025 | |
| Pfizer INC. | $63.49 | 2023-2024 | |
| Mylan Specialty L.P. | $61.74 | 2023-2024 | Yupelri |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.00 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Xeris Pharmaceuticals, INC. | $56.39 | 2023-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $43.45 | 2023-2025 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $40.84 | 2024-2025 | Voquezna |
| Lundbeck LLC | $33.12 | 2023-2025 | Vyepti |
| Sanofi-Aventis U.S. LLC | $32.87 | 2023-2024 | |
| Organon LLC | $32.09 | 2023 | Nexplanon |
| Hologic Sales and Service, LLC | $29.37 | 2024 | Myosure Tissue Removal Device |
| Ardelyx, INC. | $29.09 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $28.52 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Csl Behring | $24.81 | 2023 | Haegarda |
| Paratek Pharmaceuticals, INC. | $22.92 | 2023 | Nuzyra |
| Organogenesis INC. | $22.04 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $21.31 | 2024 | Opsumit, Uptravi |
| Vanda Pharmaceuticals INC. | $19.56 | 2025 | Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $17.63 | 2022 | |
| Averitas Pharma INC. | $16.31 | 2024 | Qutenza |
| Sanofi Pasteur INC. | $16.28 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.18 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $15.04 | 2023 | Eliquis |
| Sumitomo Pharma America, INC. | $12.64 | 2023 | Gemtesa |
| Corium, LLC | $3.78 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Sanborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.